Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 19Daunorubicin 14Etoposide 13Mitoxantrone 8Filgrastim 8Peripheral Blood Stem Cell Transplantation 6Idarubicin 6Gemtuzumab 5Cyclophosphamide 5Radiotherapy 4Observation 4valspodar 3aldesleukin 3Tretinoin 3Busulfan 3sargramostim 2Watchful Waiting 2Thioguanine 2Granulocyte Colony-Stimulating Factor 2Asparaginase 2Amsacrine 2zosuquidar trihydrochloride 1tipifarnib 1midostaurin 1lintuzumab 1laromustine 1fludarabine phosphate 1flt3 ligand protein 1etoposide phosphate 1dexamethasone acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Erythroblastic, Acute × flt3 ligand protein × Clear all
NCT00006223 2013-06-24

flt3L in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡